Fig. 6
From: USP17 is required for trafficking and oncogenic signaling of mutant EGFR in NSCLC cells
(a) A549 cells were transfected as indicated and 24 h after transfection cells were treated with the indicated dose of EGFR TKI (gefitinib) for 48 h. Cell viability was determined using an MTT assay and the results are plotted as % of untreated and un-transfected control. (b) A549 cells were transfected as indicated and 24 h after transfection, cells were treated with IC50 dose of EGFR TKI (10 μM) gefitinib for 48 h. Cell viability was determined using an MTT assay and the results are plotted as % of untreated and un-transfected control. (c) A549 cells were transfected as indicated and treated as before with the EGFR TKI (10 μM) gefitinib for 48 h. Whole cell lysates were harvested and PARP cleavage analysed by Western blotting. α-tubulin was used as a loading control. (d) A549 cells were transfected as indicated and treated as before with the EGFR TKI (10 μM) gefitinib for 48 h. The cells were fixed and cell cycle analysis was carried out by staining the cells with propidium iodide before assessment by flow cytometry (Upper panels). The percentage of cells in SubG1 (apoptotic cells) for each condition is plotted in a bar graph (Lower panel). ** p < 0.01, *** p < 0.001